Browsing Tag
AVA6000
26 posts
Avacta’s AVA6000 delivers 11.4-month PFS signal as investors await proof from lead drug AVA6103
Avacta Group plc has reported median progression-free survival of 11.4 months in a selected group of salivary gland cancer patients treated with faridoxorubicin, compared with historical benchmarks of six to 6.7 months. The findings strengthen the clinical case for its tumour-targeting technology, but differences between patient populations, a recently completed £12.5 million fundraising and the need for further clinical validation leave important questions for shareholders.
Avacta’s (AIM: AVCT) AVA6103 human data: What is proven before the 2027 efficacy test?
Avacta has reported preliminary controlled-release evidence from 19 patients treated with AVA6103, but tumour-selective delivery and clinical efficacy remain unconfirmed. Its latest £12.5 million financing places additional attention on the anticipated 2027 results.
Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus
Avacta Group’s first human AVA6103 data show controlled exatecan release and encouraging tolerability at doses above conventional exatecan’s published maximum tolerated level, strengthening the preCISION platform thesis while leaving clinical efficacy as the next decisive test.
Avacta (AIM: AVCT) clears deferred bond repayments as AVA6103 milestones shape management options
Avacta has paid another £2.61 million of its convertible bond in cash, reducing principal to £12 million, days after granting management options equivalent to about 4.1% of current issued capital.
Avacta (AIM: AVCT) share count rises 27.7% as £41.5m funding cycle splits between trials and debt
Avacta Group Plc has added approximately 102.3 million ordinary shares since the end of 2024, reducing a non-participating holder’s proportional ownership by about 21.7% while financing clinical development and lowering convertible-bond principal.
Avacta Group (AIM: AVCT) company profile: Can pre|CISION make potent cancer drugs safer and more targeted?
Avacta Group plc is developing peptide drug conjugates intended to release potent anticancer payloads primarily within the tumour microenvironment. Early AVA6000 findings and the launch of the AVA6103 trial have strengthened the scientific case, but larger clinical studies, partnership funding and management of the remaining convertible bond will determine whether pre|CISION creates sustainable shareholder value.
Avacta (AIM: AVCT) just paid down £3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.
Why Avacta’s (AVCT) smallest FAP signal could create a much bigger opportunity for pre|CISION
Avacta Group’s latest faridoxorubicin findings suggest pre|CISION may activate effectively even in tumours with minimal FAP expression, potentially widening the platform’s commercial reach while raising the importance of mature progression-free survival data and a development partnership.
Avacta just won a clean FDA path to full AVA6000 approval, so why did $AVCT barely move?
Avacta won a clean FDA path to full AVA6000 approval, yet AVCT (AIM) barely moved. The real question is whether a partner signs before cash runs low.
Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof
Avacta Group has outlined a catalyst-heavy second half of 2026, with new AVA6000 data, the first AVA6103 clinical results and potential partnering decisions set to test the commercial value of its tumour-activated oncology platform.